

Trelegy® Ellipta

- Contains fluticasone furoate (ICS) + umeclidinium (LAMA) + vilanterol (LABA)
- Once-daily, single inhaler with triple therapy, approved for long-term maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD)
- Alternative to multiple inhalers to fulfill LABA + LAMA + ICS therapy regimen, benefits include:
 - **Simplification of inhaler regimen** → patients only need to master one inhaler technique
 - **Decreased patient cost** → patients only need to pay one copay

GOLD Guidelines: Triple Therapy

- Escalate therapy to **LABA + LAMA + ICS** in patients with:
 - Persistent breathlessness or exercise limitation on LABA + ICS
 - Continued exacerbations on LABA + ICS
 - Continued exacerbations on LABA + LAMA + blood eosinophils \geq 100 cells/microliter
- ICS **not recommended** in patients with:
 - Repeat pneumonia events
 - Blood eosinophils $<$ 100 cells/microliter (may predict an increased risk of pneumonia with ICS therapy)
 - History of mycobacterial infection

Dosing

COPD: Trelegy® 100 mcg/62.5 mcg/25 mcg
one inhalation once daily

Maximum Dose: one inhalation daily

*Trelegy® 200 mcg/62.5 mcg/25 mcg is only
approved for asthma*

Not approved for use in children

Triple vs. Dual Therapy in COPD

- **IMPACT trial** → once daily LABA + LAMA + ICS compared to once daily LAMA + LABA or LABA + ICS in patients at increased risk for exacerbations demonstrated:
 - ↓ rate of moderate-to-severe exacerbations (NNT 7)
 - ↓ annual rate of hospitalizations due to severe exacerbations (NNT 17)
 - ↑ incidence of pneumonia
- **FULFIL trial** → once daily LABA + LAMA + ICS compared to twice daily LABA + ICS in patients with moderate-to-severe COPD demonstrated:
 - ↓ annual rate of moderate-to-severe exacerbations (NNT 9)
 - ↑ mean FEV₁

Prescribing Considerations

- Most common adverse reactions of Trelegy®: headache (4%), back pain (4%), altered taste (2%), diarrhea (2%)
- Patients should rinse their mouth with water after use (without swallowing) to reduce the risk of thrush
- Trelegy® is contraindicated in patients with severe hypersensitivity to milk proteins